

13th May, 2021

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Torrent Pharma Enters Into Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India

A press release issued by the Company with respect to captioned subject is attached for your information and record.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED
MAHESHKUMAR Digitally signed by
R AGRAWAL MAHESHKUMAR AGRAWAL
Date: 2021.05.13 17:51:52
+05'30'
MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl : A/a

MEDIA RELEASE



In case of any enquiry / clarification, please contact Mr. Jayesh Desai on +91 9824501396

Torrent Pharma Enters Into Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India

Ahmedabad, India 13th May 2021: Torrent Pharmaceuticals Limited (Torrent) today announced that it has entered into a royalty free, non-exclusive voluntary licensing agreement with Eli Lilly and Company, joining a group of leading Indian pharmaceutical companies for baricitinib for Covid-19 in India. Under the agreement, Lilly has provided the license to manufacture and distribute baricitinib to Torrent for India along with Lilly's other license partners.

The agreement will help ensure wider reach and access to patients in India and further adds to Torrent Pharma's effort in helping patients affected by the pandemic. Baricitinib has been approved by the Central Drug Standard Control Organisation (CDSCO), India for restricted emergency use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.

Commenting on the agreement, Aman Mehta, Chief Marketing Officer for Torrent said, "We are pleased to partner and work closely with Lilly to bring this treatment to market. This partnership further strengthens our efforts to help the nation fight the pandemic and provide quality treatment to patients. Torrent Group stands firmly committed to support the nation during this time of crisis."

About Torrent Pharmaceuticals Limited

Torrent Pharma, with annual revenues of more than Rs 7,900 crores, is the flagship Company of the Rs. 21,500 crore Torrent Group. It is ranked 8th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Central Nervous System (CNS), and Vitamins Minerals Nutrients (VMN).

It is a specialty-focused company with 76% of its revenue in India from chronic & sub-chronic therapies. It has presence in 40 countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil, Germany and Philippines. Torrent has 8 manufacturing facilities (7 in India & 1 in US), of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 700+ scientists.